CoChat

Combining surgery and immunotherapy: turning an immunosuppressive effect into a therapeutic opportunity

Open access
Bakos, Orneala, Lawson, Christine, Rouleau, Samuel, Tai, Lee-Hwa · 2018 · Journal for ImmunoTherapy of Cancer

The DOI matches its Crossref record; 105 of the 105 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Cancer surgery is necessary and life-saving. However, the majority of patients develop postoperative recurrence and metastasis, which are the main causes of cancer-related deaths. The postoperative stress response encompasses a broad set of physiological changes that have evolved to safeguard the host following major tissue trauma. These stress responses, however, intersect with cellular mediators and signaling pathways that contribute to cancer proliferation. MAIN: Previous descriptive and emerging mechanistic studies suggest that the surgery-induced prometastatic effect is linked to impairment of both innate and adaptive immunity. Existing studies that combine surgery and immunotherapies have revealed that this combination strategy is not straightforward and patients have experienced both therapeutic benefit and drawbacks. This review will specifically assess the immunological pathways that are disrupted by oncologic surgical stress and provide suggestions for rationally combining cancer surgery with immunotherapies to improve immune and treatment outcomes. SHORT CONCLUSION: Given the prevalence of surgery as frontline therapy for solid cancers, the emerging data on postoperative immunosuppression and the rapid development of immunotherapy for oncologic treatment, we believe that future targeted studies of perioperative immunotherapy are warranted.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s40425-018-0398-7

Cites

105 of 105 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Mechanisms of postoperative immunosuppression. Surgical debulking initiates inflammatory, neuroendocrine and metabolic events, which result in altered cytokine levels (decrease in IL-2, IL-12 and IFN-γ; increase in IL-6/8, IL-10 and TNF-α) and release of growth factors (VEGF - green oval, PDGF - blue oval, TGF-β - pink oval), clotting factors, and stress hormones (catecholamines - yellow circle, prostaglandins - purple circle). While essential for wound healing and pain management, these events lead to the expansion of Tregs, MDSC, and M2 macrophages. Increase in these regulatory immune cells leads to augmented expression of PD-1/CTLA-4, decreased T-cell proliferation, and impaired NK-cell cytotoxicity, resulting in an overall state of immunosuppression. In conjunctions with surgical trauma, other postoperative factors, including sepsis, blood loss, hypothermia, anesthetics, analgesics and anastomotic complications contribute to immunosuppression. Abbreviations: VEGF, vascular endothelial growth factor; PDGF, platelet-derived growth factor; TGF-β; Transforming growth factor beta; Tregs, regulatory T cells; MDSC, myeloid derived suppressor cells; PD-1, programmed cell death protein 1; CTLA-4, cytotoxic T lymphocyte associated protein 4
Fig. 1 Mechanisms of postoperative immunosuppression. Surgical debulking initiates inflammatory, neuroendocrine and metabolic events, which result in altered cytokine levels (decrease in IL-2, IL-12 and IFN-γ; increase in IL-6/8, IL-10 and TNF-α) and release of growth factors (VEGF - green oval, PDGF - blue oval, TGF-β - pink oval), clotting factors, and stress hormones (catecholamines - yellow circle, prostaglandins - purple circle). While essential for wound healing and pain management, these events lead to the expansion of Tregs, MDSC, and M2 macrophages. Increase in these regulatory immune cells leads to augmented expression of PD-1/CTLA-4, decreased T-cell proliferation, and impaired NK-cell cytotoxicity, resulting in an overall state of immunosuppression. In conjunctions with surgical trauma, other postoperative factors, including sepsis, blood loss, hypothermia, anesthetics, analgesics and anastomotic complications contribute to immunosuppression. Abbreviations: VEGF, vascular endothelial growth factor; PDGF, platelet-derived growth factor; TGF-β; Transforming growth factor beta; Tregs, regulatory T cells; MDSC, myeloid derived suppressor cells; PD-1, programmed cell death protein 1; CTLA-4, cytotoxic T lymphocyte associated protein 4CC BY · PubMed Central
Fig. 2 Combination strategies of surgery and immunotherapy. The perioperative time-frame provides a therapeutic window, which can be exploited to reduce postoperative immunosuppression and tumor growth. Perioperative use of Propranolol (β-Adrenergic inhibitor) in combination with Etodolac (COX-2 inhibitor) has been shown to reduce pro-metastatic and pro-inflammatory pathways while enhancing expression of NK-cell activation marker CD11a. Perioperative use of oncolytic viruses demonstrates lytic capability towards tumor cells, while restoring and enhancing NK- and T-cell immune cell function postoperatively. Use of PD-1/CTLA-4 inhibitors (with or without combination with microbiota) have also shown promising effects on postoperative T-cell dysfunction. Similar postoperative beneficial immune effects were observed following DC and tumor cell-based vaccines and TLR agonists. Abbreviations: PD-1, programmed cell death protein 1; DC, dendritic cells; COX-2, Prostaglandin-endoperoxide synthase 2; CTLA-4, cytotoxic T lymphocyte associated protein 4; TLR, toll like receptor
Fig. 2 Combination strategies of surgery and immunotherapy. The perioperative time-frame provides a therapeutic window, which can be exploited to reduce postoperative immunosuppression and tumor growth. Perioperative use of Propranolol (β-Adrenergic inhibitor) in combination with Etodolac (COX-2 inhibitor) has been shown to reduce pro-metastatic and pro-inflammatory pathways while enhancing expression of NK-cell activation marker CD11a. Perioperative use of oncolytic viruses demonstrates lytic capability towards tumor cells, while restoring and enhancing NK- and T-cell immune cell function postoperatively. Use of PD-1/CTLA-4 inhibitors (with or without combination with microbiota) have also shown promising effects on postoperative T-cell dysfunction. Similar postoperative beneficial immune effects were observed following DC and tumor cell-based vaccines and TLR agonists. Abbreviations: PD-1, programmed cell death protein 1; DC, dendritic cells; COX-2, Prostaglandin-endoperoxide synthase 2; CTLA-4, cytotoxic T lymphocyte associated protein 4; TLR, toll like receptorCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 105 references

Research works printed but not linked: 1

  1. Bohle W, Schlag P, Liebrich W, Hohenberger P, Manasterski M, Moiller P, et al. Postoperative active specific immunization in colorectal cancer patients with virus-modified autologous tumor-cell vaccine. First clinical results with tumor-cell vaccines modified with live but avirulent Newcastle disease virus. Cancer Immunol Immunother. 1990;66:1517–23.

Cited by

See all 192

Metadata

Authors
Bakos, O., Lawson, C., Rouleau, S., & Tai, L.-H.
Affiliations
Université de Sherbrooke (CA)
Corresponding author
Tai, Lee-Hwa
Venue
Journal for ImmunoTherapy of Cancer
Publisher
BMJ
Published
2018-09-03
Volume
6
Issue
1
Pages
86-86
ISSN
2051-1426 (ISSN-L)
OpenAlex
W2888941300
Cited by
192
References
102
Citations by year
2026: 19 · 2025: 24 · 2024: 23 · 2023: 38 · 2022: 33 · 2021: 20 · 2020: 18 · 2019: 16 · 2018: 1
FWCI
10.65
Type
journal article
Language
en
Open access
Licence
  • cc-by
  • creativecommons.org/licenses/by/4.0/ (tdm)
Locations
  • Journal for ImmunoTherapy of Cancer (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • Cancer Research Society
  • Natural Sciences and Engineering Research Council of Canada
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Stress, Anesthesia, and Immune Response
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
Keywords
cancer surgery, immunotherapy, perioperative immunotherapy, postoperative immunosuppression, surgical stress response, metastasis, postoperative recurrence, innate immunity, adaptive immunity
MeSH terms
Animals, Combined Modality Therapy, Humans, Immunosuppression Therapy, Immunotherapy, Neoplasms, Treatment Outcome, Disease Management, Cancer Vaccines, Perioperative Care, Molecular Targeted Therapy, Standard of Care

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Combining surgery and immunotherapy: turning an immunosuppressive effect into a therapeutic opportunity. https://app.cochat.ai/papers/10.1186/s40425-018-0398-7
The paper
Bakos, O., Lawson, C., Rouleau, S., & Tai, L.-H. (2018). Combining surgery and immunotherapy: turning an immunosuppressive effect into a therapeutic opportunity. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1186/s40425-018-0398-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.